MTVA MetaVia Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1638287 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY3.2%
TTM EPS YoY93.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-359.0%
ROA-129.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets74.8%
Debt / equity0.00x
Current ratio1.32x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.06x
Accruals ratio7.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $2.59M | $3.48M | $2.10M | $241,000 | $1.91M | $2.32M | $2.33M | $4.06M |
| SG&A expense | $2.10M | $1.91M | $1.92M | $1.80M | $1.56M | $1.98M | $1.56M | $1.53M |
| Operating income | -$4.69M | -$5.38M | -$4.03M | -$2.05M | -$3.48M | -$4.30M | -$3.89M | -$5.58M |
| Pretax income | -$4.62M | -$5.32M | -$3.82M | -$1.93M | -$3.38M | -$4.00M | -$3.67M | -$5.17M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$4.62M | -$5.32M | -$3.82M | -$1.93M | -$3.38M | -$4.00M | -$3.67M | -$5.17M |
| EBITDA | -$4.69M | -$5.38M | -$4.02M | -$2.04M | -$3.47M | -$4.30M | -$3.88M | -$5.58M |
| EPS (basic) | -0.69 | -0.90 | -0.79 | — | -1.52 | -2.87 | -3.93 | — |
| EPS (diluted) | -0.69 | -0.90 | -0.79 | — | -1.52 | -2.87 | -3.93 | — |
| Weighted avg. shares (diluted) | 6.68M | 5.93M | 4.86M | — | 2.22M | 1.39M | 933,109 | — |
| Banking | ||||||||
| Net interest income | $72,000 | $73,000 | $85,000 | $85,000 | $151,000 | $146,000 | $128,000 | $209,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $8.78M | $12.63M | $13.73M | $10.28M | $14.28M | $17.59M | $11.19M | $16.02M |
| Current assets | $9.35M | $13.07M | $14.16M | $10.88M | $14.65M | $18.32M | $11.96M | $16.07M |
| PP&E, net | $22,000 | $8,000 | $12,000 | $17,000 | $22,000 | $27,000 | $30,000 | $34,000 |
| Total assets | $9.55M | $13.27M | $14.39M | $11.12M | $14.77M | $18.46M | $12.13M | $16.26M |
| Current liabilities | $7.06M | $6.35M | $5.19M | $5.65M | $8.43M | $8.82M | $7.71M | $8.27M |
| Total liabilities | $7.14M | $6.45M | $5.32M | $5.79M | $8.43M | $8.84M | $7.75M | $8.33M |
| Shareholders' equity | $2.41M | $6.82M | $9.07M | $5.33M | $6.33M | $9.62M | $4.38M | $7.93M |
| Shares outstanding | 6.74M | 6.58M | 5.16M | 2.31M | 24.21M | 24.19M | 8.65M | 785,194 |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.72M | -$3.76M | -$4.26M | -$4.86M | -$2.96M | -$3.07M | -$4.82M | -$5.43M |
| Capital expenditure | — | — | — | $0 | $0 | — | — | $0 |
| Free cash flow | — | — | — | -$4.86M | -$2.96M | — | — | -$5.43M |
| Investing cash flow | — | — | — | $0 | $0 | — | — | $0 |
| Financing cash flow | -$117,000 | $2.67M | $7.71M | $861,000 | -$357,000 | $9.47M | -$12,000 | -$224,000 |
| Depreciation & amortization | $7,000 | $4,000 | $5,000 | $5,000 | $5,000 | $5,000 | $4,000 | $5,000 |
| Stock-based compensation | $135,000 | $130,000 | $100,000 | $71,000 | $97,000 | $111,000 | $132,000 | $160,000 |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.